Network-Guided Multiomic Mapping of Aortic Valve Calcification
Overview
Affiliations
Despite devastating clinical sequelae of calcific aortic valve disease that range from left ventricular remodeling to arrhythmias, heart failure, and early death, the molecular insights into disease initiation and progression are limited and pharmacotherapies remain unavailable. The pathobiology of calcific aortic valve disease is complex and comprehensive studies are challenging valvular calcification is heterogeneous and occurs preferentially on the aortic surface, along a fibrocalcific spectrum. Here, we review efforts to study (epi-)genomic, transcriptomic, proteomic, and metabolomic aspects of aortic valve calcification in combination with network medicine-/systems biology-based strategies to integrate multilayered omics datasets and prioritize druggable targets for experimental validation studies. Ultimately, such holistic approach efforts may open therapeutic avenues that go beyond invasive and costly valve replacement therapy.
Calcific aortic stenosis: omics-based target discovery and therapy development.
Blaser M, Back M, Luscher T, Aikawa E Eur Heart J. 2024; 46(7):620-634.
PMID: 39656785 PMC: 11825147. DOI: 10.1093/eurheartj/ehae829.
Immunotherapy in the Context of Aortic Valve Diseases.
Bartoli-Leonard F, Pennel T, Caputo M Cardiovasc Drugs Ther. 2024; 38(6):1173-1185.
PMID: 39017904 PMC: 11680629. DOI: 10.1007/s10557-024-07608-7.
Jain H, Goyal A, Khan A, Khan N, Jain J, Chopra S Ann Med Surg (Lond). 2024; 86(6):3577-3590.
PMID: 38846838 PMC: 11152847. DOI: 10.1097/MS9.0000000000002106.
Chen J, Ren T, Xie L, Hu H, Li X, Maitusong M Nat Commun. 2024; 15(1):557.
PMID: 38228638 PMC: 10792006. DOI: 10.1038/s41467-024-44726-0.